News

AMA urges FDA to require clinical trials for botanical drug products

By Ella Ruder 1 min read

The American Medical Association is calling on the FDA to require botanical drug products, including kratom and cannabis, to prove safety and efficacy in clinical trials before they are marketed or prescribed, warning that unproven products can pose serious risks to patients. The AMA made its case in an Oct. 28 letter to FDA Deputy Commissioner Grace Graham. The physician group argued that rising consumer demand, anecdotal claims and influencer marketing on social media should not replace high-quality clinical trials or postmarket safety monitoring. AMA President Willie Underwood III, MD,… Originally published in Becker’s Hospital Review. Read More

Share this post

Integrated Psychiatric Consultants

Office Hours:
Mon-Fri, 9 a.m. - 5 p.m. CT

Reach out today.

Integrated Psychiatric Consultants (IPC) is committed to protecting and respecting your privacy. Our team will use the information collected here solely to serve your needs and notify you about relevant services. To consent, please check the box above and submit this form.

Please note, this consent applies to all forms of communications, including SMS. If you have provided a mobile phone number above, you agree to receiving SMS messages from IPC. You may unsubscribe at any time. Message frequency varies. Messaging and data rates may apply. Reply STOP to cancel. For more information, please review our Privacy Policy.